7-hydroxystaurosporine has been researched along with Ovarian Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, T; Berchuck, A; Cory Barnett, J; Fujii, S; Kondoh, E; Konishi, I; Matsumura, N; Mori, S; Murphy, SK; Whitaker, RS; Yamaguchi, K | 1 |
| Brown, S; Chen, EX; Dancey, JE; Hirte, HW; Hotte, SJ; Moore, M; Oza, A; Pond, GR; Winquist, EW | 1 |
| Brown, S; Carey, MS; Dancey, JE; Hirte, HW; Hotte, SJ; Oza, AM; Pond, GR; Tsao, MS; Welch, S | 1 |
| Aghajanian, C; Husain, A; Rosales, N; Schwartz, GK; Spriggs, DR; Yan, XJ | 1 |
2 trial(s) available for 7-hydroxystaurosporine and Ovarian Neoplasms
| Article | Year |
|---|---|
Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Salivary Gland Neoplasms; Staurosporine; Survival Analysis; Topotecan | 2006 |
UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a study of the Princess Margaret Hospital Phase II consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Staurosporine; Topotecan | 2007 |
2 other study(ies) available for 7-hydroxystaurosporine and Ovarian Neoplasms
| Article | Year |
|---|---|
Targeting slow-proliferating ovarian cancer cells.
Topics: Antineoplastic Agents; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytostatic Agents; Disease-Free Survival; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Ki-67 Antigen; Ovarian Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Staurosporine | 2010 |
UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II)independent of p53 status.
Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Cisplatin; Drug Synergism; Female; Genes, p53; Humans; Mutagenesis; Ovarian Neoplasms; Recombinant Proteins; Staurosporine; Time Factors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1997 |